ClinicalTrials.gg
CompletedNCT04840901Updated Nov 22, 2024Results posted

A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants

A Phase 1 interventional study of Lebrikizumab in Healthy, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-22.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
242
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to look at the amount of the study drug, lebrikizumab, that gets into the blood stream and how long it takes the body to get rid of lebrikizumab (LY3650150) when given using either a pre-filled autoinjector (AI) or a pre-filled syringe with needle safety device (PFS-NSD). The safety and tolerability of lebrikizumab will also be evaluated. The study will last up to 102 days.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are Overtly healthy males or nonpregnant females of childbearing or non- as determined through medical evaluation.
  • Agree not to donate blood or plasma until after the end of their participation in the study
  • Have a (BMI) within the range 18.0 to 32.0 kilograms per meter squared (kg/m²)

Exclusion criteria

Exclusion Criteria:

  • Are females who are pregnant or lactating.
  • Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
  • Have a history or presence of psychiatric disorders
  • Show evidence of infection.
  • Show evidence of and/or
  • Medical history of allergic reaction to humanized monoclonal antibodies
  • Have had lymphoma, leukemia, or any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years.
  • Are currently enrolled in any other clinical study involving an product or any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Smoke more than 10 cigarettes per day or the equivalent including electronic cigarettes or are unable to abide by CRU smoking restrictions
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
242 participants (actual)

Study arms

  • Experimental
    Lebrikizumab (Reference) - Pre-Filled Syringe with Needle Safety Device

    2-milliliter (mL) (125 milligrams per milliliter \[mg/mL\]) Lebrikizumab administered subcutaneously (SC) via pre-filled syringe with needle safety device (PFS-NSD).

    Drug: Lebrikizumab

  • Experimental
    Lebrikizumab (Test) - Autoinjector

    2-mL (125 mg/mL) Lebrikizumab administered SC via autoinjector (AI).

    Drug: Lebrikizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lebrikizumab

    PK: Cmax of Lebrikizumab

    Time frame: Predose: Day 1, and Postdose: Days 3, 5, 8, 11, 15, 22, 29, 43, 57, 71, 85, and 99

  2. PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Lebrikizumab

    PK: AUC\[0-∞\] of Lebrikizumab

    Time frame: Predose: Day 1, and Postdose: Days 3, 5, 8, 11, 15, 22, 29, 43, 57, 71, 85, and 99

  3. PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Lebrikizumab

    PK: AUC\[0-tlast\] of Lebrikizumab

    Time frame: Predose: Day 1, and Postdose: Days 3, 5, 8, 11, 15, 22, 29, 43, 57, 71, 85, and 99

07

Results

Posted Nov 22, 2024

Participant flow

Participant flow — Overall Study
MilestoneLebrikizumab (Reference) - Pre-Filled Syringe With Needle Safety Device (PFS-NSD)Lebrikizumab (Test) - Autoinjector (AI)
Started123119
Received at least one dose of study drug122119
Completed118117
Not completed52
Withdrew: Lost to follow-up31
Withdrew: Moved10
Withdrew: Unable to comply with study schedule01
Withdrew: Screen failure - randomized but did not receive study drug10

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Lebrikizumab

PK: Cmax of Lebrikizumab

Time frame:
Predose: Day 1, and Postdose: Days 3, 5, 8, 11, 15, 22, 29, 43, 57, 71, 85, and 99
Reported as:
Geometric mean · micrograms per milliliter (µg/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lebrikizumab
micrograms per milliliter (µg/mL)Lebrikizumab (Reference) - Pre-Filled Syringe With Needle Safety Device (PFS-NSD)Lebrikizumab (Test) - Autoinjector (AI)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Lebrikizumab38.5 ± 3141.9 ± 31
Statistical analysis
  • Lebrikizumab (Reference) - Pre-Filled Syringe With Needle Safety Device (PFS-NSD) vs Lebrikizumab (Test) - Autoinjector (AI) · ANCOVA · Ratio of geometric ls mean: 1.09 · 90% CI 1.03 to 1.16
PrimaryPK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Lebrikizumab

PK: AUC\[0-∞\] of Lebrikizumab

Time frame:
Predose: Day 1, and Postdose: Days 3, 5, 8, 11, 15, 22, 29, 43, 57, 71, 85, and 99
Reported as:
Geometric mean · micrograms*day per milliliter (µg*d/mL)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Lebrikizumab
micrograms*day per milliliter (µg*d/mL)Lebrikizumab (Reference) - Pre-Filled Syringe With Needle Safety Device (PFS-NSD)Lebrikizumab (Test) - Autoinjector (AI)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Lebrikizumab1340 ± 291450 ± 26
Statistical analysis
  • Lebrikizumab (Reference) - Pre-Filled Syringe With Needle Safety Device (PFS-NSD) vs Lebrikizumab (Test) - Autoinjector (AI) · ANCOVA · Ratio of geometric ls mean: 1.07 · 90% CI 1.02 to 1.14
PrimaryPK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Lebrikizumab

PK: AUC\[0-tlast\] of Lebrikizumab

Time frame:
Predose: Day 1, and Postdose: Days 3, 5, 8, 11, 15, 22, 29, 43, 57, 71, 85, and 99
Reported as:
Geometric mean · µg*d/mL
PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Lebrikizumab
µg*d/mLLebrikizumab (Reference) - Pre-Filled Syringe With Needle Safety Device (PFS-NSD)Lebrikizumab (Test) - Autoinjector (AI)
PK: Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of Lebrikizumab1250 ± 281360 ± 25
Statistical analysis
  • Lebrikizumab (Reference) - Pre-Filled Syringe With Needle Safety Device (PFS-NSD) vs Lebrikizumab (Test) - Autoinjector (AI) · ANCOVA · Ratio of geometric ls mean: 1.09 · 90% CI 1.03 to 1.14

Adverse events

Collected over Up to 99 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lebrikizumab (Reference) - Pre-Filled Syringe With Needle Safety Device (PFS-NSD)0/122 (0%)0/122 (0%)39/122 (32%)
Lebrikizumab (Test) - Autoinjector (AI)0/119 (0%)0/119 (0%)26/119 (21.8%)
Most frequent other events
Showing 10 of 63
Most frequent other events
EventLebrikizumab (Reference) - Pre-Filled Syringe With Needle Safety Device (PFS-NSD)Lebrikizumab (Test) - Autoinjector (AI)
HeadacheNervous system disorders15/1227/119
COVID-19Infections and infestations7/1223/119
Menstruation irregularReproductive system and breast disorders0/732/64
DiarrhoeaGastrointestinal disorders0/1223/119
NauseaGastrointestinal disorders0/1223/119
Injection site reactionGeneral disorders0/1223/119
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/1223/119
VomitingGastrointestinal disorders2/1222/119
PainGeneral disorders1/1222/119
PyrexiaGeneral disorders0/1222/119

Baseline characteristics

All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Lebrikizumab (Reference) - Pre-Filled Syringe With Needle Safety Device (PFS-NSD)Lebrikizumab (Test) - Autoinjector (AI)Total
Mean45.2 ± 12.644.1 ± 13.244.7 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)Lebrikizumab (Reference) - Pre-Filled Syringe With Needle Safety Device (PFS-NSD)Lebrikizumab (Test) - Autoinjector (AI)Total
Female7364137
Male4955104
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lebrikizumab (Reference) - Pre-Filled Syringe With Needle Safety Device (PFS-NSD)Lebrikizumab (Test) - Autoinjector (AI)Total
Hispanic or Latino203050
Not Hispanic or Latino10288190
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lebrikizumab (Reference) - Pre-Filled Syringe With Needle Safety Device (PFS-NSD)Lebrikizumab (Test) - Autoinjector (AI)Total
American Indian or Alaska Native213
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American282755
White9190181
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Lebrikizumab (Reference) - Pre-Filled Syringe With Needle Safety Device (PFS-NSD)Lebrikizumab (Test) - Autoinjector (AI)Total
United States122119241
08

Study locations

4 sites
  • LabCorp CRU, Inc.
    Daytona Beach, Florida 32117, United States
  • QPS
    Springfield, Missouri 65802, United States
  • Covance Dallas
    Dallas, Texas 75247, United States
  • LabCorp CRU, Inc.
    Madison, Wisconsin 53704, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Feb 2022, 8 months.

Results were first posted in Nov 2024, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2021
First posted
Apr 12, 2021
StartActual
Jun 2, 2021
Primary completionActual
Feb 11, 2022
CompletionActual
Feb 11, 2022
Results first posted
Nov 22, 2024
Last update
Nov 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04840901
Responsible party
Sponsor
First posted
Apr 12, 2021
Start date
Jun 2, 2021
Primary completion
Feb 11, 2022
Completion
Feb 11, 2022
Results posted
Nov 22, 2024
Last update
Nov 22, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion